Detected ·
iFAST Diagnostics
——
iFAST Diagnostics raised £5M ($6.7M) in new funding led by Meridian Health Ventures, with participation from QantX, Raw Ventures, OKG Capital, Cambridge Capital Group, and £2.1M non-dilutive loan from Innovate UK. The company develops ultrafast antibiotic susceptibility tests (3hrs vs 48hrs) to combat antimicrobial resistance.
- Website
- ifastdiagnostics.com
- Amount
- —
- Stage
- —
- Event
- Funding round
- Detected
- 2026-05-28 16:01:43 UTC
- Signal ID
- 815688c7-95a3-412e-904b-2a8e4faa1202
As the API returns it
{
"id": "815688c7-95a3-412e-904b-2a8e4faa1202",
"created_at": "2026-05-28T16:01:43.282042Z",
"company_name": "iFAST Diagnostics",
"company_website_url": "ifastdiagnostics.com",
"company_linkedin_url": "https://www.linkedin.com/company/ifast-diagnostics",
"event_type": "funding",
"funding_amount": null,
"funding_currency": null,
"funding_stage": null,
"message": "*iFAST Diagnostics raised £5M ($6.7M) in new funding led by Meridian Health Ventures, with participation from QantX, Raw Ventures, OKG Capital, Cambridge Capital Group, and £2.1M non-dilutive loan from Innovate UK. The company develops ultrafast antibiotic susceptibility tests (3hrs vs 48hrs) to combat antimicrobial resistance.*"
}